Welcome to our dedicated page for Kamada news (Ticker: KMDA), a resource for investors and traders seeking the latest updates and insights on Kamada stock.
Kamada Ltd. develops, produces and markets specialty plasma-derived therapeutics and other biopharmaceutical products for rare and serious conditions. News about KMDA commonly covers financial results and guidance, commercial performance of products such as KAMRAB, GLASSIA, HEPAGAM, VARIZIG, WINRHO and CYTOGAM, and supply arrangements for blood-product markets.
Company updates also address plasma collection operations, including FDA-cleared facilities in Texas, product distribution activity, dividend policy and withholding-tax procedures for ordinary-share distributions. Kamada is traded on Nasdaq and the Tel Aviv Stock Exchange.
Kamada Ltd. (NASDAQ: KMDA), a global biopharmaceutical company specializing in plasma-derived therapeutics, announced that Amir London, CEO, will present at the Credit Suisse 31st Annual Healthcare Conference on November 8, 2022, at 3:50 p.m. ET. Additionally, Mr. London will be available for virtual one-on-one investor meetings during the event. Interested investors should contact their Credit Suisse representative. The presentation will be accessible via a live webcast on Kamada's investor relations page, with a replay available for 30 days.
Kamada Ltd. (NASDAQ: KMDA) announced an extension of its supply tender with Canadian Blood Services for four specialty IgG products, securing about $7.5 million per year from 2023-2025, totaling approximately $22 million. The products, acquired in 2021, include CYTOGAM®, HEPAGAM®, VARIZIG®, and WINRHO® SDF. The deal reinforces Kamada’s position in the Canadian market and follows a recent $11.4 million agreement for VARIZIG in Latin America. Manufacturing of CYTOGAM is set to begin in 2023 at Kamada's Israeli facility, pending regulatory approvals.
Kamada Ltd. (NASDAQ: KMDA) reported second quarter 2022 revenues of $23.6 million, down 3% from $24.2 million year-over-year, while first half revenues rose 5% to $51.7 million. Adjusted EBITDA for H1 2022 was $4.6 million, with a cash flow increase to $29.9 million. The company is optimistic about a stronger second half, reiterating fiscal year revenue guidance of $125-$135 million, reflecting 20%-30% growth. Challenges include a $3.3 million loss due to a labor strike and increased operating expenses. The firm anticipates growth from new IgG products and royalty income from GLASSIA.
Kamada Ltd. (NASDAQ: KMDA) will release its Q2 and first-half financial results on August 17, 2022, before U.S. market open. An investment community conference call will follow at 8:30 AM ET, with participation options provided. The company focuses on specialty plasma-derived therapeutics, boasting a diverse portfolio including FDA-approved products such as GLASSIA® and KEDRAB®. Kamada also has a robust development pipeline, particularly in inhaled AAT therapy for AAT deficiency, currently in a pivotal Phase 3 trial.
Kamada Ltd. (Nasdaq: KMDA) announced on July 15, 2022, the signing of a new collective agreement with the Employees’ Union of its Beit Kama production facility and the Histadrut, effective until 2029. This agreement resulted in the resolution of a previously disclosed labor strike, allowing employees to return to work. Despite this, the company anticipates a negative impact on its second quarter financial results due to a one-time loss linked to the work stoppage, although it did not affect the availability of commercial products.
Kamada Ltd. (NASDAQ: KMDA) has secured an $11.4 million agreement to supply VARIZIG® to an undisclosed international organization focused on Latin America. The product supply is anticipated from the fourth quarter of 2022 to the first half of 2023. This agreement highlights Kamada’s expanding international presence and the commercial potential of their FDA-approved plasma-derived therapies. VARIZIG is crucial for post-exposure prophylaxis of chickenpox in high-risk patients, and is the only FDA-approved IgG product for this use.
Kamada Ltd. (NASDAQ: KMDA) has promoted Shavit Beladev to Vice President of Plasma Operations and Boris Gorelik to Vice President of Business Development. Ms. Beladev, with over 20 years at Kamada, will manage the U.S. plasma collection expansion, while Mr. Gorelik will focus on business development and strategic partnerships. CEO Amir London emphasized these promotions align with the company's strategy to enhance its U.S. presence in specialty plasma therapeutics. Kamada is known for its diverse portfolio of FDA-approved plasma-derived products and ongoing clinical trials.
STADA is launching Hukyndra®, a high-concentration, citrate-free biosimilar to adalimumab, in select European markets including France, Germany, Finland, and Sweden. This launch follows approval from the European Commission and represents the first product from STADA's partnership with Alvotech. Hukyndra® is designed to enhance patient comfort with reduced injection-site pain. The biosimilar is approved for treating various inflammatory conditions, supporting patient access to vital therapies in Europe.
Kamada Ltd. (NASDAQ: KMDA) announced a virtual meeting on June 7, 2022, to discuss growth catalysts. Presenters include CEO Amir London and CFO Chaime Orlev. The company projects 2022 revenue of $125M-$135M, a 20%-30% increase from 2021, with EBITDA margins of 12-15%. Key growth initiatives include expanding U.S. sales, entering the plasma collection market in Texas, and increasing royalties from GLASSIA®. Kamada also aims to distribute 11 biosimilars in Israel with anticipated peak sales of over $40M. The company is enrolling for a Phase 3 study of inhaled AAT for AAT deficiency.
Kamada Ltd. reported Q1 2022 revenues of $28.1 million, a 13% year-over-year increase. The company reiterated its full-year revenue guidance of $125 million to $135 million, projecting a 20% to 30% growth compared to 2021. Gross margins improved to 40%, up from 36% in Q1 2021. Kamada generated $5.5 million in operating cash flows, raising total available cash to $22 million. The company noted a net loss of $1.8 million in the quarter, mainly impacted by increased operating expenses due to R&D and sales efforts.